Cargando…

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102

BACKGROUND: ADS‐5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS‐5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Stuart H., Fahn, Stanley, Pahwa, Rajesh, Tanner, Caroline M., Espay, Alberto J., Trenkwalder, Claudia, Adler, Charles H., Patni, Rajiv, Johnson, Reed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947645/ https://www.ncbi.nlm.nih.gov/pubmed/29780852 http://dx.doi.org/10.1002/mdc3.12595

Ejemplares similares

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment
por: Cohen, Jeffrey A, et al.
Publicado: (2021)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
por: Hauser, Robert A., et al.
Publicado: (2021)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia
por: Sharma, Vibhash D., et al.
Publicado: (2020)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease
por: Lin, Iris, et al.
Publicado: (2023)

Secondary Metabolites with Nitric Oxide Inhibition from Marine-Derived Fungus Alternaria sp. 5102
por: Chen, Senhua, et al.
Publicado: (2020)

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
por: Hauser, Robert A., et al.
Publicado: (2019)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease
por: Greene, Paul E., et al.
Publicado: (2021)

Tardive Dyskinesia in Older Persons Taking Antipsychotics
por: Citrome, Leslie, et al.
Publicado: (2021)

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
por: Isaacson, Stuart H, et al.
Publicado: (2022)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study
por: Hammond, Flora M., et al.
Publicado: (2015)

A Conservative Approach to the Management of a Dental Trauma for Immediate Natural Esthetics
por: Mahesh Patni, Pallav, et al.
Publicado: (2016)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

Paraneoplastic Chorea Managed with Intravenous Amantadine
por: Doher, Nicholas, et al.
Publicado: (2019)

Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses
por: Nguyen, Jack T., et al.
Publicado: (2012)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations
por: Jackson, Richard, et al.
Publicado: (2021)

Effects of amantadine on circulating neurotransmitters in healthy subjects
por: Lechin, Fuad, et al.
Publicado: (2010)

Amantadine-induced livedo reticularis - Case report
por: Quaresma, Maria Victória, et al.
Publicado: (2015)

Amantadine for the Treatment of Refractory Absence Seizures in Children
por: Sreedharan, Mini, et al.
Publicado: (2018)

Simple and Economical Process for Producing Amantadine Hydrochloride
por: Phan Thi, Phuong Dung, et al.
Publicado: (2022)

Amantadine Toxicity in Apostichopus japonicus Revealed by Proteomics
por: Zhao, Junqiang, et al.
Publicado: (2023)

Comparison of LC-MS(3) and LC-MRM Methods for Quantifying Amantadine and Its Application in Therapeutic Amantadine Monitoring in Human Plasma
por: Sun, Qiang, et al.
Publicado: (2022)

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
por: Isaacson, Stuart H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85j6qpvophfisq6099cot4rucu